Zobrazit minimální záznam

Primary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imaging

dc.contributor.authorŠuráňová, Markéta
dc.contributor.authorĎuriš, Miroslav
dc.contributor.authorŠtenglová Netíková, Irena
dc.contributor.authorBrábek, Jan
dc.contributor.authorHorák, Tomáš
dc.contributor.authorJůzová, Veronika
dc.contributor.authorChmelík, Radim
dc.contributor.authorVeselý, Pavel
dc.date.accessioned2023-07-11T14:10:22Z
dc.date.available2023-07-11T14:10:22Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.14178/1975
dc.description.abstractSolid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented.en
dc.language.isoen
dc.relation.urlhttps://doi.org/10.1364/BOE.488630
dc.rightsCreative Commons Uveďte původ 4.0 Internationalcs
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.titlePrimary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imagingen
dcterms.accessRightsopenAccess
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/legalcode
dc.date.updated2023-11-07T08:14:05Z
dc.subject.keywordsolid canceren
dc.subject.keywordmetastasesen
dc.subject.keywordmigrastaticsen
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5102
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/COOP/COOP
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/FN/V-FN/V-VFN
dc.date.embargoStartDate2023-11-07
dc.type.obd73
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.identifier.doi10.1364/BOE.488630
dc.identifier.utWos001019493200004
dc.identifier.eidScopus2-s2.0-85162036715
dc.identifier.obd633099
dc.identifier.pubmed37342686
dc.subject.rivPrimary30000::30200::30204
dc.subject.rivSecondary10000::10600::10608
dc.subject.rivSecondary30000::30500::30502
dcterms.isPartOf.nameBiomedical Optics Express
dcterms.isPartOf.issn2156-7085
dcterms.isPartOf.journalYear2023
dcterms.isPartOf.journalVolume14
dcterms.isPartOf.journalIssue6
uk.faculty.primaryId115
uk.faculty.primaryNamePřírodovědecká fakultacs
uk.faculty.primaryNameFaculty of Scienceen
uk.faculty.secondaryId53
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazecs
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazeen
uk.department.primaryId1035
uk.department.primaryNameKatedra buněčné biologiecs
uk.department.primaryNameDepartment of Cell Biologyen
uk.department.secondaryId5000002624
uk.department.secondaryNameÚsek léčebné péčecs
uk.department.secondaryNameÚsek léčebné péčeen
dc.description.pageRange2689-2708
dc.type.obdHierarchyCsČLÁNEK V ČASOPISU::článek v časopisu::původní článekcs
dc.type.obdHierarchyEnJOURNAL ARTICLE::journal article::original articleen
dc.type.obdHierarchyCode73::152::206en
uk.displayTitlePrimary assessment of medicines for expected migrastatic potential with holographic incoherent quantitative phase imagingen


Soubory tohoto záznamu

Thumbnail
Název:
boe-14-6-2689.pdf
Velikost:
3.998Mb
Formát:
PDF
Zobrazit/otevřít

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam